Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Victoria Mateos

Showing results (21-30 of 231) with videos related to

Pageof 24
Sort By:
Leukemia|October 17, 2020
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVORKatja Weisel, Maria-Victoria Mateos, Francesca Gay, et al.
British Journal of Haematology|November 24, 2018
Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016Marc S Raab, Leah Fink, Paul Schoen, et al.
Journal of Hematology & Oncology|April 5, 2018
Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE studyMeletios Dimopoulos, Michael Wang, Vladimir Maisnar, et al.
British Journal of Haematology|August 19, 2022
Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcomeCristina De Ramón, Elizabeta A Rojas, Ignacio J Cardona-Benavides, et al.
Expert Review of Clinical Pharmacology|June 20, 2022
Melflufen for the treatment of multiple myelomaEnrique M Ocio, Omar Nadeem, Fredrik Schjesvold, et al.
Blood Cancer Journal|July 17, 2023
Global disparities in patients with multiple myeloma: a rapid evidence assessmentMaria-Victoria Mateos, Sikander Ailawadhi, Luciano J Costa, et al.
Drugs of Today (Barcelona, Spain : 1998)|August 19, 2022
Melphalan flufenamide for relapsed/refractory multiple myelomaOmar Nadeem, Maria-Victoria Mateos, Yvonne A Efebera, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 30, 2019
Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysisHervé Avet-Loiseau, Heinz Ludwig, Ola Landgren, et al.
European Journal of Haematology|May 22, 2019
Understanding mortality in multiple myeloma: Findings of a European retrospective chart reviewMohamad Mohty, Michele Cavo, Leah Fink, et al.
Blood Cancer Journal|February 24, 2019
Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myelomaHeinz Ludwig, Philippe Moreau, Meletios A Dimopoulos, et al.
Pageof 24

Showing results (21-30 of 231) with videos related to

Sort By:
Pageof 24
Leukemia|October 17, 2020
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVORKatja Weisel, Maria-Victoria Mateos, Francesca Gay, et al.
British Journal of Haematology|November 24, 2018
Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016Marc S Raab, Leah Fink, Paul Schoen, et al.
Journal of Hematology & Oncology|April 5, 2018
Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE studyMeletios Dimopoulos, Michael Wang, Vladimir Maisnar, et al.
British Journal of Haematology|August 19, 2022
Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcomeCristina De Ramón, Elizabeta A Rojas, Ignacio J Cardona-Benavides, et al.
Expert Review of Clinical Pharmacology|June 20, 2022
Melflufen for the treatment of multiple myelomaEnrique M Ocio, Omar Nadeem, Fredrik Schjesvold, et al.
Blood Cancer Journal|July 17, 2023
Global disparities in patients with multiple myeloma: a rapid evidence assessmentMaria-Victoria Mateos, Sikander Ailawadhi, Luciano J Costa, et al.
Drugs of Today (Barcelona, Spain : 1998)|August 19, 2022
Melphalan flufenamide for relapsed/refractory multiple myelomaOmar Nadeem, Maria-Victoria Mateos, Yvonne A Efebera, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 30, 2019
Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysisHervé Avet-Loiseau, Heinz Ludwig, Ola Landgren, et al.
European Journal of Haematology|May 22, 2019
Understanding mortality in multiple myeloma: Findings of a European retrospective chart reviewMohamad Mohty, Michele Cavo, Leah Fink, et al.
Blood Cancer Journal|February 24, 2019
Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myelomaHeinz Ludwig, Philippe Moreau, Meletios A Dimopoulos, et al.
Pageof 24